

REMARKS/ARGUMENTS

I. Support for Claim Amendments

Applicants appreciate the thoughtful comments and suggestions in the Examiner's July 13, 2007 Office Action. Per the Examiner's suggestion on pages 2-3 of the Office Action, Applicants have amended claims 1 and 31-33 to delete the term, "selectively."

Independent claims 1 and 32 have been amended to recite the term "human subject." Support for this amendment may be found in the specification at, *e.g.*, paragraph 229 (describing microarray analysis of human tissue using Affymetrix chips to detect FGFR2, shown in Table 4).

Claims 1 and 31-33 have also been amended to recite the limitation of using a nucleic acid probe that is "at least 95% complementary to SEQ ID NO:1." Support for this claim may be found in the specification at paragraphs 72-76 (describing methods of hybridizing identical and substantially identical nucleic acids); at paragraphs 112-127 (describing hybridization techniques for detecting levels of mRNA expression); paragraph 229 (describing microarray analysis using Affymetrix chips to detect genes identified in Table 4, including FGFR2); and Table 5 (confirming the Affymetrix chip data by RT-PCR measurements of FGFR2 mRNA expression).

Claims 1 and 32 have also been amended to address a possible antecedent basis issue arising from the earlier amendments to the claims. Specifically, the phrase "said polynucleotide" has been deleted and replaced with the phrase, "said subject's FGFR2 mRNA," *i.e.*, the molecule whose diminished expression correlates with major depression disorder, as shown by Applicants. Support for this amendment is found in the specification at, *e.g.*, paragraph 229 (describing microarray analysis using Affymetrix chips to detect genes identified in Table 4 including FGFR2 (pages 1 and 10)); Table 1; Table 2; Table 5; Fig. 4 and Fig. 14 (confirming the Affymetrix chip data by RT-PCR measurements of FGFR2 mRNA expression).

New claims 34 and 35 depend from claims 1 and 32, respectively, and limit the claimed methods to the use of probes which are "at least 95% identical to the full-length complement of SEQ ID NO:1." Support for this claim may be found in the specification at, *e.g.*, paragraphs 72-76 (describing methods of hybridizing identical and substantially identical nucleic acids); and at

paragraphs 112-127 (describing hybridization techniques for detecting levels of mRNA expression).

Thus, no new matter is added by any of the forgoing amendments to the claims.

II. Rejection of Claims 1 and 32 under 35 U.S.C. § 112, paragraph 2 (indefiniteness)

On page 2 of the Office Action, the Examiner rejected claims 1 and 32 under 35 U.S.C. § 112, paragraph 2 as indefinite. Specifically, the Examiner argued that the term "selectively" (as in "selectively associates") was "not defined" and would not be readily understood by one of skill in the art. In the interest of advancing prosecution, Applicants have deleted the phrase from the pending claims. Withdrawal of the Examiner's indefiniteness rejection is earnestly solicited.

III. Rejection of Claims 1 and 31-33 under 35 U.S.C. § 112, paragraph 1 (written description)

On pages 3-5 of the Office Action, the Examiner rejected claims 1 and 31-33 as failing to comply with the written description requirement. Specifically, the Examiner objects to language describing the use of "a nucleic acid probe which is at least 95% complementary to *mRNA encoding FGFR2*." The Examiner argues on one hand that "mRNA encoding FGFR2" includes mRNA "which could be from any species," including species allegedly not disclosed in Applicants' specification. Applicants' have expressly limited the claims to the detection of *human* FGFR2 mRNA to address at least this aspect of the Examiner's argument.

While acknowledging that the specification "reasonably provides support for contacting nucleic acid [*sic*] with a nucleic acid at least 95% identical to SEQ ID NO:1," the Examiner objects to the phrase "*mRNA encoding FGFR2*" because (the Examiner argues) undisclosed sequences could "encode" FGFR2 yet have less than 95% identity to SEQ ID NO:1. As discussed above, Applicants have deleted the offending phrase and the claimed methods now recite the use of a nucleic acid probe that is "at least 95% complementary to SEQ ID NO:1."

Lastly, the Examiner appears to argue that the existence of a relatively "limited sub-genus of mRNAs that encode FGFR2" requires that Applicants limit their claimed methods to probes that are "at least 95% identical to the full-length complement of SEQ ID NO:1." Applicants respectfully submit that the Examiner is misapplying the "written description requirement" in

this particular instance. The Examiner's proposed limitation does not fairly capture the full scope of what Applicants have invented *and described* as their invention.

Applicants acknowledge the Federal Circuit's holding that the enablement and written description requirements are, to some extent, non-overlapping. *See, e.g.*, MPEP 2164, citing *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563 (Fed. Cir. 1991) ("the purpose of the 'written description' requirement is broader than to merely explain how to 'make and use'"). However, Applicants respectfully remind the Examiner that the same panel of CAFC judges held that "the fundamental factual inquiry [for evaluating written description] is whether the specification conveys with *reasonable clarity* to those skilled in the art that, as of the filing date sought, applicant was in possession of the invention as now claimed." *See id.* at 1563-64. Thus, the state of the art and the knowledge of one skilled in the art is a relevant consideration.¹ Here, the sequences of FGFR2 mRNA are readily available in the art (as well as in Applicants' specification). Similarly, hybridization techniques for measuring expression are routine (and also described in Applicants' specification).

Applicants' specification both enables *and* conveys possession of their claimed invention with *reasonable clarity*. Specifically, Applicants' specification shows that FGFR2 transcription can be measured using probes based on the GenBank M80634, Z71929, M87771 and M87770 sequences for FGFR2. *See, e.g.*, paragraph 229, Table 1, Table 2, Table 4 (pages 1 and 10), and Figure 4. While each of these four mRNA sequences differ, Applicants' specification shows that probes designed to measure expression of the mRNAs yielded the same result, *i.e.*, diminished expression of FGFR2 mRNA (regardless of the isoform) is associated with an increased likelihood of major depression disorder.² Applicants' specification also shows that other nucleic acid hybridization-based techniques, *e.g.*, real-time PCR, can be used successfully in their method to achieve the same result. *See, e.g.*, Figure 14. Taking the data and specification as a

¹ In this regard, Applicants note that the Examiner has admitted that Applicants' specification is enabling for "detecting *expression of human FGFR2 receptor nucleic acid* in the dorsolateral prefrontal cortex of a deceased patient and concluding that the patient had major depression disorder." *See* October 24, 2006 Office Action at page 5. At the time of this earlier Office Action, the existence of minor isoforms and/or carboxy-terminal splice variants of mRNA encoding the FGFR2 receptor was evidently (and appropriately) not considered a significant issue by the Examiner.

² An Appendix showing the mRNA sequences of M80634, Z71929, M87771, and M87770 is attached.

whole, one skilled in the art would reasonably understand that Applicants possessed the invention as described by the Examiner in the earlier Office Action: a method for “detecting expression of human FGFR2 receptor nucleic acid” and correlating that expression with major depression disorder. Precedent supports this result. *See, e.g., Capon v. Eshhar*, 418 F.3d 1349 (2005) (“when the prior art includes the nucleotide information, precedent does not set a *per se* rule that the information must be determined afresh”).


Finally, Applicants note that they are not attempting to claim a broad genus of new nucleic acid *compositions*, nor a broad method for inhibiting the translation of FGFR2 (or one of its isoforms) using nucleic acid probes. If either were the case, the strict treatment given to Applicants’ claims under the written description requirement might be warranted. Instead, Applicants’ pending claims are diagnostic *method* claims that comprise, in part, well-known and routinely optimizable nucleic acid hybridization techniques using nucleic acid probe sequences that are readily found in the prior art. As noted above, the Examiner previously indicated that Applicants’ methods are enabled and, since that time, Applicants have narrowed their claims considerably by, *e.g.*, reciting a discrete FGFR2 reference sequence (*i.e.*, SEQ ID NO.1).

For all the forgoing reasons, Applicants respectfully request withdrawal of the Examiner’s written description rejection.

CONCLUSION

Applicants believe all claims now pending in this Application are in condition for allowance. At this stage in prosecution, Applicants have found that any remaining issues are most efficiently resolved by a formal Interview. If the Examiner believes that one or more of the present claims are still not allowable for some reason, Applicants respectfully ask the Examiner to telephone the undersigned at 925-472-5000 so an Interview can be promptly arranged.

Respectfully submitted,



Chris J. Ullsperger
Reg. No. 48,006

Appl. No. 10/701,263
Amdt. dated November 13, 2007
Reply to Office Action of February 13, 2006

PATENT

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 415-576-0300
CJU:jc

61203327 v1

APPENDIX: FGFR2 mRNA SEQUENCES

M80634: mRNA

LOCUS HUMKGFRA 3106 bp mRNA linear PRI 27-APR-1993
DEFINITION Human keratinocyte growth factor receptor mRNA, complete cds.
ACCESSION M80634
VERSION M80634.1 GI:186740
KEYWORDS keratinocyte growth factor receptor.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 3106)
AUTHORS Miki,T., Bottaro,D.P., Fleming,T.P., Smith,C.L., Burgess,W.H.,
Chan,A.M. and Aaronson,S.A.
TITLE Determination of ligand-binding specificity by alternative
splicing: two distinct growth factor receptors encoded by a
single
gene
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 89 (1), 246-250 (1992)
PUBMED 1309608
COMMENT Original source text: Homo sapiens Mammary gland cDNA to mRNA.
FEATURES
source 1..3106
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/cell_line="B5/589"
/cell_type="Epithelial cell"
/tissue_type="Mammary gland"
CDS 419..2887
/note="putative"
/codon_start=1
/product="keratinocyte growth factor receptor"
/protein_id="AAA36147.1"
/db_xref="GI:186741"

/translation="MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTYQI
SQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDS
GLYACTASRTVDSETWYFMVNVTDAISSGDDDDTDGAEDFVSENSNNKRAPYWTNTE
KMEKRLHAVPAANTVKFRCPAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIM
ESVVPSDKGNYTCVVENEYGSINHTYHLDVVERSPhRPILQAGLPANASTVVGGDVEF
VCKVYSDAQPHIQWIKHVEKNGSKYGPDGLPYLKVLKHSGINSSNAEVLALFNVTEAD
AGEYICKVSNIYGQANQSAWLTVLPKQQAPGREKEITASPDYLEIAIYCIGVFLIACM
VVTVILCRMKNNTTKKPDFSSQPAVHKLTkRIPLRRQVTVSAESSSSMNSNTPLVRITT

RLSSTADTPMLAGVSEYELPEDPKWEFPDRDKLTLGKPLGEGCFGQVMAEAVGIDKDK
 PKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKMIGKHKNIINLLGACTQDGPLYVIVE
 YASKGNLREYLRARRPPGMEYSYDINRVPEEQMTFKDLVSCITYQLARRMEYLASQKCI
 HRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKTNGRLPVKWMapeALFDRVYT
 HQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDC
 WHAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYSPSPYDTRSSCSSGDDSV
 FSPDPMPIYEPCLPQYPHINGSVKT"

ORIGIN

1	cccgcgagca	aagtttggtg	gaggcaacgc	aagcctgagt	cctttcttcc	tctcgttccc
61	caaataccgag	ggcagcccgc	gggcgtcatg	gcgctcctcc	gcagcctggg	gtacgcgtga
121	agcccgggag	gcttggcgcc	ggcgaagacc	caaggaccac	tcttctgcgt	ttggagttgc
181	tccccgcaac	cccgggctcg	tcgctttctc	catcccgacc	cacgcggggc	cggggacaac
241	acaggtcgcg	gaggagcgtt	gccattcaag	tgactgcagc	agcagcgag	cgctcggtt
301	cctgagccca	ccgcagctga	aggcattgcg	cgtagtccat	gcccgtagag	gaagtgtgca
361	gatgggatta	acgtccacat	ggagatatgg	aagaggaccg	gggattggta	ccgtaaccat
421	ggtcagctgg	ggtcgtttca	tctgcctggt	cgtggtcacc	atggcaacct	tgtccctggc
481	ccggccctcc	ttcagtttag	ttgaggatac	cacattagag	ccagaagagc	caccaacca
541	ataccaaatc	tctcaaccag	aagtgtacgt	ggctgcgcca	ggggagtcgc	tagaggtgcg
601	ctgcctggtg	aaagatgccg	ccgtgatcag	ttggactaag	gatgggggtg	acttggggcc
661	caacaatagg	acagtgccta	ttggggagta	cttgacagata	aagggcgcca	cacctagaga
721	ctccggcctc	tatgcttgta	ctgccagtag	gactgtagac	agtgaactt	ggtacttcat
781	ggtgaatgtc	acagatgcc	tctcatccgg	agatgatgag	gatgacaccg	atggtgcgga
841	agattttgtc	agtgagaaca	gtaacaacaa	gagagcacca	tactggacca	acacagaaaa
901	gatggaaaag	cggctccatg	ctgtgcctgc	ggccaacact	gtcaagtttc	gctgcccgac
961	cggggggaac	ccaatgcca	ccatgcggtg	gctgaaaaac	gggaaggagt	ttaagcagga
1021	gcatacgcat	ggaggctaca	aggtacgaaa	ccagcactgg	agcctatta	tggaaagtgt
1081	ggtcccatct	gacaaggga	attatacctg	tgtagtggag	aatgaatacg	ggtccatcaa
1141	tcacacgtac	cacctggatg	ttgtggagcg	atgcctcac	cggcccatcc	tccaagccgg
1201	actgcccga	aatgcctcca	cagtggctcg	aggagacgta	gagtttgtct	gcaaggttta
1261	cagtgatgcc	cagccccaca	tccagtggat	caagcacgtg	gaaaagaacg	gcagtaata
1321	cggggccgac	gggctgccct	acctcaaggt	tctcaagcac	tcggggataa	atagttccaa
1381	tgcagaagtg	ctggctctgt	tcaatgtgac	cgaggcggat	gctggggaat	atatatgtaa
1441	ggtctccaat	tatatagggc	aggccaacca	gtctgcctgg	ctcactgtcc	tgccaaaaca
1501	gcaagcgcc	ggaagagaaa	aggagattac	agcttcccca	gactacctgg	agatagccat
1561	ttactgcata	ggggtcttct	taatgcctg	tatggtggta	acagtcatcc	tgtgccgaat
1621	gaagaacacg	accaagaagc	cagacttcag	cagccagccg	gctgtgcaca	agctgaccaa
1681	acgtatcccc	ctgcggagac	aggtaacagt	ttcggtgag	tccagctcct	ccatgaactc
1741	caacaccccg	ctggtgagga	taacaacacg	cctctcttca	acggcagaca	ccccatgct
1801	ggcaggggtc	tccgagtatg	aacttccaga	ggacccaaaa	tgggagtttc	caagagataa
1861	gctgacactg	ggcaagcccc	tgggagaagg	ttgctttggg	caagtgggtca	tggcggaagc
1921	agtgggaatt	gacaaagaca	agcccaagga	ggcggtcacc	gtggccgtga	agatgttgaa
1981	agatgatgcc	acagagaaa	acctttctga	tctggtgtca	gagatggaga	tgatgaagat
2041	gattgggaaa	cacaagaata	tcataaatct	tcttggagcc	tgacacagc	atgggcctct
2101	ctatgtcata	gttgagtatg	cctctaaagg	caacctcoga	gaataacctc	gagcccgag
2161	gccacccggg	atggagtact	cctatgacat	taacgtgtgt	cctgaggagc	agatgacctt
2221	caaggacttg	gtgtcatgca	cctaccagct	ggccagacgg	atggagtact	tggcttccca
2281	aaaatgtatt	catcgagatt	tagcagccag	aaatgttttg	gtaacagaaa	acaatgtgat
2341	gaaaatagca	gactttggac	tcgccagaga	tatcaacaat	atagactatt	acaaaaagac
2401	caccaatggg	cggcttccag	tcaagtggat	ggctccagaa	gcctgttttg	atagagtata
2461	cactcatcag	agtgatgtct	ggctcctcgg	ggtgttaatg	tgggagatct	tacttttagg
2521	gggctcgccc	taccagggga	ttcccgtaga	ggaacttttt	aagctgctga	aggaaggaca

2581 cagaatggat aagccagcca actgcaccaa cgaactgtac atgatgatga gggactggtg
 2641 gcatgcagtg cctcccaga gaccaacgtt caagcagttg gtagaagact tggatcgaat
 2701 tctcactctc acaaccaatg aggaatactt ggacctcagc caacctctcg aacagtattc
 2761 acctagttac cctgacacaa gaagttcttg ttcttcagga gatgattctg tttttctcc
 2821 agaccccatg cttacgaac catgccttcc tcagtatcca cacataaacg gcagtgttaa
 2881 aacatgaatg actgtgtctg cctgtcccca aacaggacag cactgggaac ctagctacac
 2941 tgagcagga gaccatgcct cccagagctt gttgtctcca cttgtatata tggatcagag
 3001 gagtaaataa ttggaaaagt aatcagcata tgtgtaaaga tttatacagt tgaaaacttg
 3061 taatcttccc caggaggaga agaaggttcc tggagcagtg gactgc

Z71929: mRNA

LOCUS Z71929 3248 bp mRNA linear PRI 14-NOV-2006

DEFINITION H.sapiens FGFR2 mRNA.

ACCESSION Z71929

VERSION Z71929.1 GI:1296624

KEYWORDS FGFR2 gene.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.

REFERENCE 1

AUTHORS Steinberger,D. and Mueller,U.

TITLE New point mutations in FGFR2 associated with Crouzon Syndrome

JOURNAL Unpublished

REMARK (sites)

REFERENCE 2 (bases 1 to 3248)

AUTHORS Steinberger,D.

TITLE Direct Submission

JOURNAL Submitted (25-APR-1996) Steinberger D., Institute for Humangenetics, Schlangenzahl 14, Giessen, Germany, 35392

FEATURES Location/Qualifiers

source 1..3248
/organism="Homo sapiens"
/mol_type="mRNA"
/isolate="proband 113"
/db_xref="taxon:9606"
/chromosome="10q26"
/tissue_type="blood"

gene 1..3248
/gene="FGFR2"

CDS 13..2478
/gene="FGFR2"
/codon_start=1
/protein_id="CAA96492.1"
/db_xref="GI:1296625"
/db_xref="GDB:127273"
/db_xref="GOA:P21802"
/db_xref="HGNC:3689"
/db_xref="InterPro:IPR000719"
/db_xref="InterPro:IPR001245"
/db_xref="InterPro:IPR003598"
/db_xref="InterPro:IPR007110"
/db_xref="InterPro:IPR008266"
/db_xref="InterPro:IPR011009"
/db_xref="InterPro:IPR013151"
/db_xref="InterPro:IPR013783"
/db_xref="PDB:1DJS"
/db_xref="PDB:1E00"
/db_xref="PDB:1EV2"
/db_xref="PDB:1GJO"
/db_xref="PDB:1II4"
/db_xref="PDB:1IIL"

/db_xref="PDB:1NUN"
 /db_xref="PDB:1OEC"
 /db_xref="PDB:2FDB"
 /db_xref="UniProtKB/Swiss-Prot:P21802"

/translation="MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQI
 SQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDS
 GLYACTASRTVDSETWYFMVNVTDAISSGDEDDTDGAEDFVSENSNNKRAPYWTNTE
 KMEKRLHAVPAANTVKFRCPAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIM
 ESVVPSDKGNYTCVVENEYGSINHTYHLDVVERSHPRPILQAGLPANASTVVGGDVEF
 VCKVYSDAQPHIQWIKHVEKNGSKYGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTF
 EDAGEYTCLAGNSIGISFHSAWLTVLPAPGREKEITASPDYLEIAIYCIGVFLIACMV
 VTVILCRMKNNTTKKPDFSSQPAVHKLTKRIPLRRQVTVSAESSSSMNSNTPLVRITTR
 LSSTADTPMLAGVSEYELPEDPKWEFPRDKLTLGKPLGEGCFGQVVM AEAVGIDKDKP
 KEAVTVAVKMLKDDATEKDLSDLVSEMEMMKMIGKHKNIIINLLGACTQDGPLYVIVEY
 ASKGNLREYLRARRPPGMEYSYDINRVPEEQMTFKDLVSCITYQLARGMEYLASQKCIH
 RDLAARNVLVTENNVMKIADFG LARDINNIDYKKT TNRLPVKWM APEALFDRVYTH
 QSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCW
 HAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYSPSPDTRSSCSSGDDSVF

variation 1037
 /gene="FGFR2"
 /note="g(1037)->c; Cys342->Ser"
 /phenotype="Crouzon Syndrome"
 /replace="g"

ORIGIN

1	ggtaccgtaa	ccatggctcag	ctgggggtcgt	ttcatctgcc	tggtcgtggt	caccatggca
61	accttgtccc	tggcccggcc	ctccttcagt	ttagttgagg	ataccacatt	agagccagaa
121	gagccaccaa	ccaaatacca	aatctctcaa	ccagaagtgt	acgtggctgc	accaggggag
181	tcgctagagg	tgcgctgcct	gttgaaagat	gccgccgtga	tcagttggac	taaggatggg
241	gtgcacttgg	ggcccaacaa	taggacagtg	cttattgggg	agtacttgca	gataaagggc
301	gccacgccta	gagactccgg	cctctatgct	tgtactgcca	gtaggactgt	agacagtgaa
361	acttggtact	tcattggtgaa	tgtcacagat	gccatctcat	ccggagatga	tgaggatgac
421	accgatggtg	cggaagattt	tgtcagttag	aacagtaaca	acaagagagc	accatactgg
481	accaacacag	aaaagatgga	aaagcggctc	catgctgtgc	ctgcggccaa	cactgtcaag
541	tttcgctgcc	cagccggggg	gaacccaatg	ccaaccatgc	ggtggctgaa	aaacgggaag
601	gagtttaagc	aggagcatcg	cattggaggc	tacaaggtag	gaaaccagca	ctggagcctc
661	attatggaaa	gtgtggtccc	atctgacaag	ggaaattata	cctgtgtggt	ggagaatgaa
721	tacgggtcca	tcaatcacac	gtaccacctg	gatgttgtgg	agcgatcgcc	tcaccggccc
781	atcctccaag	ccggactgcc	ggcaaatgcc	tccacagtgg	tcggaggaga	cgtagagttt
841	gtctgcaagg	tttacagtga	tgccagcccc	cacatccagt	ggatcaagca	cgtggaaaag
901	aacggcagta	aatacggggc	cgacgggctg	ccctacctca	aggttctcaa	ggccgcccgt
961	gttaacacca	cggacaaaga	gattgaggtt	ctctatattc	ggaatgtaac	ttttgaggac
1021	gctgggggaat	atacgtgctt	ggcgggtaat	tctattggga	tatcctttca	ctctgcatgg

1081 ttgacagttc tggcagcgcc tggaagagaa aaggagatta cagcttcccc agactacctg
1141 gagatagcca tttactgcat aggggtcttc ttaatcgctt gtatgggtgg aacagtcac
1201 ctgtgccgaa tgaagaacac gaccaagaag ccagacttca gcagccagcc ggctgtgcac
1261 aagctgacca aacgtatccc cctgcggaga caggtaacag tttcggctga gtccagctcc
1321 tccatgaact ccaacacccc gctgggtgag ataacaacac gcctctcttc aacggcagac
1381 acccccatgc tggcaggggt ctccgagtat gaacttccag aggacccaaa atgggagttt
1441 ccaagagata agctgacact gggcaagccc ctgggagaag gttgcttttg gcaagtggtc
1501 atggcggaag cagtgggaat tgacaaagac aagcccaagg aggcggtcac cgtggccgtg
1561 aagatgttga aagatgatgc cacagagaaa gacctttctg atctgggtgc agagatggag
1621 atgatgaaga tgattgggaa acacaagaat atcataaatc ttcttgagc ctgcacacag
1681 gatgggcctc tctatgtcat agttgagtat gcctctaaag gcaacctccg agaataacct
1741 cgagcccggg gggcaccggg gatggagtac tcctatgaca ttaaccgtgt tccatgaggag
1801 cagatgacct tcaaggactt ggtgtcatgc acctaccagc tggccagagg catggagtac
1861 ttggcttccc aaaaatgtat tcatcgagat ttagcagcca gaaatgtttt ggtaacagaa
1921 aacaatgtga tgaaaatagc agacttttga ctgccagag atatcaacaa tatagactat
1981 tacaaaaaga ccaccaatgg gcggttcca gtcaagtggg tggctccaga agcctgtttt
2041 gatagagtat acactcatca gagtgatgtc tggctcttcg ggggtttaat gtgggagatc
2101 ttcacttttag ggggtctgcc ctaccaggg attcccgagg aggaactttt taagctgctg
2161 aaggaaggac acagaatgga taagccagcc aactgcacca acgaactgta catgatgatg
2221 agggactgtt ggcattgcagt gccctcccag agaccaacgt tcaagcagtt ggtagaagac
2281 ttggatcgaa ttctcactct cacaaccaat gaggaatact tggacctcag ccaacctctc
2341 gaacagtatt cactagtta ccctgacaca agaagttctt gttcttcagg agatgattct
2401 gttttttctc cagaccccat gccttacgaa ccatgccttc ctcatgatcc acacataaac
2461 ggcagtgtta aaacatgaat gactgtgtct gcctgtcccc aaacaggaca gcaactggaa
2521 cctagctaca ctgagcaggg agaccatgcc tcccagagct tgttgtctcc acttgtatat
2581 atggatcaga ggagtaaata attggaaaag taatcagcat atgtgtaaag atttatacag
2641 ttgaaaactt gtaatcttcc ccaggaggag aagaagggtt ctggagcagt ggactgccac
2701 aagccaccat gtaacccctc tcacctgccg tgcgtactgg ctgtggacca gtaggactca
2761 aggtggacgt gcgttctgcc ttcttgttga attttgtaat aattggagaa gatttatgtc
2821 agcacacact tacagagcac aaatgcagta tatagggtgt ggatgtatgt aaatatattc
2881 aaattatgta taaatatata ttatatattt acaaggagtt attttttga ttgattttaa
2941 atggatgtcc caatgcacct agaaaattgg tctctctttt tttaatagct atttgctaaa
3001 tgctgttctt acacataatt tcttaatttt caccgagcag aggtggaaaa atacttttgc
3061 tttcagggaa aatggtataa cgttaattta ttaataaatt ggtaatatat aaaacaatta
3121 atcatttata gttttttttg taatttaagt ggcatttcta tgcaggcagc acagcagact
3181 agttaatcta ttgcttggac ttaactagtt atcagatcct ttgaaaagag aatattttaca
3241 atatatga

M87771: mRNA

LOCUS HUMKSAMIII 3244 bp mRNA linear PRI 06-JAN-1995
DEFINITION Human secreted fibroblast growth factor receptor (K-sam-III) mRNA,
complete cds.
ACCESSION M87771
VERSION M87771.1 GI:186781
KEYWORDS K-sam-III; fibroblast growth factor receptor.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 3244)
AUTHORS Kato, M., Hattori, Y., Sasaki, H., Tanaka, M., Sugano, K., Yazaki, Y., Sugimura, T. and Terada, M.
TITLE K-sam gene encodes secreted as well as transmembrane receptor tyrosine kinase
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 89 (7), 2960-2964 (1992)
PUBMED 1313574
COMMENT Original source text: Homo sapiens cDNA to mRNA.
FEATURES
Location/Qualifiers
source 1..3244
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/cell_line="NCC-IT"
gene 1..3244
/gene="K-sam-III"
CDS 488..2605
/gene="K-sam-III"
/codon_start=1
/product="fibroblast growth factor receptor"
/protein_id="AAA59471.1"
/db_xref="GI:186782"

/translation="MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQI
SQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDS
GLYACTASRTVDSETWYFMVNVTDAISSGDDDDTDGAEDFVSENSNNKRAPYWTNTE
KMEKRLHAVPAANTVKFRCPAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIM
ESVVP SDKGNYTCVVENEYGSINHTYHLDVVERS PHRPILQAGLPANASTVVGGDVEF
VCKVYSDAQPHIQWIKHVEKNGSKYGPDGLPYLKV LKVS AESSSSMNSNTPLVRITTR
LSSTADTPMLAGVSEYELPEDPKWEFPRDKLTLGKPLGEGCFGQVMAEAVGIDKDKP
KEAVTVAVKMLKDDATEKDLSDLVSEMEMMKMIGKHKNIIINLLGACTQDGPLYVIVEY
ASKGNLREYLRARRPPGMEYSYDINRVPEEQMTFKDLVSCITYQLARGMEYLASQKCIH

RDLAARNVLVTENNVMKIADFGGLARDINNIDYYKKTNGRLPVKWMapeALFDRVYTH

QSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKpanCTNELYMMMRDCW

HAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYSPSPDTRSSCSSGDDSVF

SPDPMPEPCLPQYPHINGSVKT"

sig_peptide

488..550

/gene="K-sam-III"

ORIGIN

```
1  ccggccgcga  gccccggggg  ccccgaggcc  gcagcttgcc  tgcgcgctct  gagccttcgc
61  aactcgcgag  caaagtttgg  tggaggcaac  gccaaagcctg  agtcctttct  tcctctcggt
121  ccccaaatec  gagggcagcc  cgcgggcgct  atgcccgcgc  tcctccgcag  cctgggggtac
181  gcgtgaagcc  cgggaggctt  ggcgcggcgc  aagacccaag  gaccactctt  ctgcgtttgg
241  agttgctccc  cccaacccc  ggctcgtcgc  tttctccatc  ccgaccacgc  cggggcgcgg
301  ggacaacaca  ggtcgcggag  gagcggttgc  attcaagtga  ctgcagcagc  agcggcagcg
361  cctcggttcc  tgagcccacc  gcaggctgaa  ggcattgcgc  gtagtccatg  cccgtagagg
421  aagtgtgcag  atgggattaa  cgtccacatg  gagatatgga  agaggaccgc  ggattggtac
481  cgtaaccatg  gtcagctggg  gtcgtttcat  ctgcctgggc  gtggtcacca  tggcaacctt
541  gtccctggcc  cggccctcct  tcagtttagt  tgaggatacc  acattagagc  cagaagagcc
601  accaaccaaa  taccaaatec  ctcaaccaga  agtgtacgtg  gctgcgccag  gggagtcgct
661  agaggtgcgc  tgcctgttga  aagatgccgc  cgtgatcagt  tggactaagg  atgggggtga
721  cttggggccc  aacaatagga  cagtgcctat  tggggagtac  ttgcagataa  agggcgccac
781  gcctagagac  tccggcctct  atgcttgtag  tgccagtagg  actgtagaca  gtgaaacttg
841  gtacttcatg  gtgaatgtca  cagatgccat  ctcatccgga  gatgatgagg  atgacaccga
901  tgggtgcggaa  gattttgtca  gtgagaacag  taacaacaag  agagcaccat  actggaccaa
961  cacagaaaag  atggaaaagc  ggctccatgc  tgtgcttgcg  gccaaactgc  tcaagtttgc
1021  ctgcccagcc  ggggggaacc  caatgccaac  catgcggtgg  ctgaaaaacg  ggaaggagtt
1081  taagcaggag  catcgcattg  gaggtacaaa  ggtacgaaac  cagcactgga  gcctcattat
1141  ggaaagtgtg  gtcccactct  acaagggaaa  ttatacctgt  gtggtggaga  atgatacagg
1201  gtccatcaat  cacacgtacc  acctggatgt  tgtggagcga  tcgcctcacc  ggcccatcct
1261  ccaagccgga  ctgccggcaa  atgctccac  agtggtcgga  ggagacgtag  agtttgtctg
1321  caaggtttac  agtgatgcc  agccccacat  ccagtggatc  aagcacgtgg  aaaagaacgg
1381  cagtaaatac  gggcccgacg  ggctgcccta  cctcaagggt  ctcaagggtt  cggctgagtc
1441  cagctcctcc  atgaactcca  acaccccgct  ggtgaggata  acaacacgcc  tctcttcaac
1501  ggcagacacc  cccatgctgg  caggggtctc  cgagtatgaa  cttccagagg  acccaaatg
1561  ggagtttcca  agagataagc  tgacactggg  caagcccctg  ggagaagggt  gctttgggca
1621  agtggctcat  gcggaagcag  tgggaattga  caaagacaag  cccaaggagg  cggtcaccgt
1681  ggcggtgaag  atgttgaaag  atgatgccac  agagaaagac  ctttctgatc  tgggtgcaga
1741  gatggagatg  atgaagatga  ttgggaaaca  caagaatatc  ataaatcttc  ttggagcctg
1801  cacacaggat  gggcctctct  atgtcatagt  tgagtatgcc  tctaaaggca  acctccgaga
1861  atacctccga  gcccgagggc  cccccgggat  ggagtactcc  tatgacatta  accgtgttcc
1921  tgaggagcag  atgaccttca  aggacttggt  gtcatgcacc  taccagctgg  ccagaggcat
1981  ggagtacttg  gcttcccaaa  aatgtattca  tcgagattta  gcagccagaa  atgttttggg
2041  aacagaaaac  aatgtgatga  aaatagcaga  ctttggactc  gccagagata  tcaacaatat
2101  agactattac  aaaaagacca  ccaatgggcg  gcttccagtc  aagtggatgg  ctccagaagc
2161  cctgtttgat  agagtataca  ctcatcagag  tgatgtctgg  tccttcgggg  tgtaaatgtg
2221  ggagatcttc  actttagggg  gctcgcccta  cccagggatt  cccgtggagg  aactttttaa
2281  gctgctgaag  gaaggacaca  gaatggataa  gccagccaac  tgcaccaacg  aactgtacat
2341  gatgatgagg  gactgttggc  atgcagtgcc  ctccagaga  ccaacgttca  agcagttggt
2401  agaagacttg  gatogaattc  tcactctcac  aaccaatgag  gaatacttgg  acctcagcca
2461  acctctcgaa  cagtattcac  ctagttaacc  tgacacaaga  agttcttgtt  cttcaggaga
2521  tgattctgtt  ttttctccag  accccatgcc  ttacgaacca  tgcttctctc  agtatccaca
2581  cataaacggc  agtgttaaaa  catgaatgac  tgtgtctgcc  tgtcccaaaa  caggacagca
2641  ctgggaacct  agctacactg  agcagggaga  ccatgcctcc  cagagcttgt  tgtctccact
2701  tgtatatatg  gatcagagga  gtaaataatt  ggaaaagtaa  tcagcatatg  tgtaaagatt
2761  tatacagttg  aaaacttgta  atcttcccca  ggaggagaag  aaggtttctg  gagcagtgga
```

2821	ctgccacaag	ccaccatgta	acccctctca	cctgccgtgc	gttctggctg	tggaaccagta
2881	ggactcaagg	tggaacgtgcg	ttctgccttc	cttggttaatt	ttgtaataat	tggaagaagat
2941	ttatgtcagc	acacacttac	agagcacaaa	tgcaagtatat	aggtgctgga	tgtatgtaaa
3001	tatattcaaa	ttatgtataa	atataatatta	tatatttaca	aggagttatt	ttttgtattg
3061	atttttaaag	gatgtcccaa	tgcacctaga	aaattggtct	ctcttttttt	aatagctatt
3121	tgctaaatgc	tggtcttaca	cataatttct	taattttcac	cgagcagagg	tggaataata
3181	cttttgcttt	cagggaaaat	ggtataacgt	taatttatta	ataaattggt	aatatacaaa
3241	acaa					

M87770: mRNA

LOCUS HUMKSAMI 4268 bp mRNA linear PRI 06-JAN-1995
DEFINITION Human fibroblast growth factor receptor (K-sam) mRNA, complete cds.
ACCESSION M87770
VERSION M87770.1 GI:186779
KEYWORDS K-sam-I; fibroblast growth factor.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 4268)
AUTHORS Katoh,M., Hattori,Y., Sasaki,H., Tanaka,M., Sugano,K., Yazaki,Y., Sugimura,T. and Terada,M.
TITLE K-sam gene encodes secreted as well as transmembrane receptor tyrosine kinase
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 89 (7), 2960-2964 (1992)
PUBMED 1313574
COMMENT Original source text: Homo sapiens brain cDNA to mRNA.
FEATURES
Location/Qualifiers
source 1..4268
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/tissue_type="brain"
gene 1..4268
/gene="K-sam-I"
CDS 274..2739
/gene="K-sam-I"
/codon_start=1
/product="fibroblast growth factor receptor"
/protein_id="AAA59470.1"
/db_xref="GI:186780"

/translation="MVSWGRFICLVVVMTATLSLARPSFSLVEDTTLEPEEPPTKYQI
SQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLI GEYLQIKGATPRDS
GLYACTASRTVDSETWYFMVNVTDAISSGDDDDTDGAEDFVSENSNNKRAPYWTNTE
KMEKRLHAVPAANTVKFRCPAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIM
ESVVP SDKGNYTCVVENEYGSINHTYHLDVVERS PHRPILQAGLPANASTVVGGDVEF
VCKVYSDAQPHIQWIKHVEKNGSKYGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTF
EDAGEYTCLAGNSIGISFHSAWLTVLPAPGREKEITASPDYLEIAIYCIGVFLIACMV
VTVILCRMKNTTKKPDFSSQPAVHKLT KRIPLRRQVTVSAESSSSMNSNTPLVRITTR
LSSTADTPMLAGVSEYELPEDPKWEFFPRDKLT LGKPLGEGCFGQVVM AEAVGIDKDKP
KEAVTVAVKMLKDDATEKDLSDLVSEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEY

ASKGNLREYLRARRPPGMEYSYDINRVPEEQMTFKDLVSCTYQLARGMEYLASQKCIH

RDLAARNVLVTENNVMKIADFGGLARDINNIDYYKKTNGRLPVKWMAPEALFDRVYTH

QSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCW

HAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYSPSYPDTRSSCSSGDDSVF

SPDPMPYEPCLPQYPHINGSVKT"

sig peptide

274..336

/gene="K-sam-I"

ORIGIN

```
1  cccaaggacc  actcttctgc  gtttgaggat  gctccccaca  accccgggct  cgtcgttttc
61  tccatcccga  cccacgcggg  ggcgggggac  aacacaggtc  gcggaggagc  gttgccattc
121 aagtgactgc  agcagcagcg  gcagcgctc  ggttcctgag  cccaccgcag  gctgaaggca
181 ttgcgcgtag  tccatgcccg  tagaggaagt  gtgcagatgg  gattaacgtc  cacatggaga
241 tatggaagag  gaccggggat  tggtagcgta  accatggtca  gctggggctg  tttcatctgc
301 ctggtcgtgg  tcaccatggc  aaccttgtcc  ctggcccggc  cctccttcag  tttagttgag
361 gataccacat  tagagccaga  agagccacca  accaaatacc  aaatctctca  accagaagtg
421 tacgtggctg  cgccagggga  gtcgctagag  gtgcgctgcc  tgttgaaaga  tgccgccgtg
481 atcagttgga  ctaaggatgg  ggtgcacttg  gggcccaaca  ataggacagt  gcttattggg
541 gagtacttgc  agataaaggg  cgccacgcct  agagactccg  gcctctatgc  ttgtactgcc
601 agtaggactg  tagacagtga  aacttggtac  ttcattggtg  atgtcacaga  tgccatctca
661 tccggagatg  atgaggatga  caccgatgg  gcggaagatt  ttgtcagtga  gaacagtaac
721 aacaagagag  caccatactg  gaccaacaca  gaaaagatgg  aaaagcggct  ccatgctgtg
781 cctgcggcca  aactgtcaa  gtttcgctgc  ccagccgggg  ggaaccaat  gccaaccatg
841 cggtggtgta  aaaacgggaa  ggagtttaag  caggagcatc  gcattggagg  ctacaaggta
901 cgaaaccagc  actggagcct  cattatggaa  agtgtggtcc  catctgacaa  gggaaattat
961 acctgtgtgg  tggagaatga  atacgggtcc  atcaatcaca  cgtaccacct  ggtgttgtg
1021 ggcgatcgc  ctcaccggcc  catcctcaa  gccggactgc  cggcaaatgc  ctccacagtg
1081 gtcggaggag  acgtagagtt  tgtctgcaag  gtttacagtg  atgccagacc  ccacatccag
1141 tggatcaagc  acgtggaaaa  gaacggcagt  aaatacgggc  ccgacgggct  gccctacctc
1201 aaggttctca  aggcgcggcg  tgtaaacacc  acggacaaag  agattgaggt  tctctatatt
1261 cggaatgtaa  cttttgagga  cgctggggaa  tatacgtgct  tggcgggtaa  ttctattggg
1321 atatcctttc  actctgcatg  gttgacagtt  ctgccagcgc  ctggaagaga  aaaggagatt
1381 acagcttccc  cagactacct  ggagatagcc  atttactgca  taggggtctt  cttaatcgcc
1441 tgtatggtgg  taacagtcac  cctgtgccga  atgaagaaca  cgaccaagaa  gccagacttc
1501 agcagccagc  cggctgtgca  caagctgacc  aaacgtatcc  ccctgcggag  acaggtaaca
1561 gtttcggctg  agtccagctc  ctccatgaac  tccaacaccc  cgctggtgag  gataacaaca
1621 cgctctctct  caacggcaga  ccccccatg  ctggcagggg  tctccgagta  tgaacttcca
1681 gaggacccaa  aatgggagtt  tccaagagat  aagctgacac  tgggcaagcc  cctgggagaa
1741 ggttgctttg  ggcaagtgg  catggcggaa  gcagtgggaa  ttgacaaaga  caagcccaag
1801 gaggcgggtc  ccgtggccgt  gaagatggtg  aaagatgatg  ccacagagaa  agacctttct
1861 gatctgggtg  cagagatgga  gatgatgaag  atgattggga  aacacaagaa  tatcataaat
1921 cttcttgagg  cctgcacaca  ggatgggcct  ctctatgtca  tagttgagta  tgctctaaa
1981 ggcaacctcc  gagaatacct  ccgagcccg  aggccaccgc  ggatggagta  ctctatgac
2041 attaacctg  ttcttgagga  gcagatgacc  ttcaaggact  tgggtgcatg  cactaccag
2101 ctggccagag  gcatggagta  cttggccttc  caaaaatgta  ttcacogaga  tttagcagcc
2161 agaaatgttt  tggtaacaga  aaacaatgtg  atgaaaatag  cagactttgg  actcgccaga
2221 gatataca  atatagacta  ttacaaaag  accaccaatg  ggcggttcc  agtcaagtgg
2281 atggctccag  aagccctgtt  tgatagagta  tacactcatc  agagtgatgt  ctggctcttc
2341 ggggtgttaa  tgtgggagat  cttcacttta  gggggctcgc  cctaccagg  gattcccgtg
2401 gaggaacttt  ttaagctgct  gaaggaagga  cacagaatgg  ataagccagc  caactgcacc
2461 aacgaactgt  acatgatgat  gagggactgt  tggcatgcag  tgccctccca  gagaccaacg
2521 ttcaagcagt  tggtagaaga  cttggatcga  attctcactc  tcacaacca  tgaggaatac
2581 ttggacctca  gccaacctct  cgaacagtat  tcacctagtt  accctgacac  aagaagttct
2641 tgttcttcag  gagatgattc  tgttttttct  ccagacccca  tgcttacga  accatgcctt
```

2701	cctcagtatc	cacacataaa	cggcagtggt	aaaacatgaa	tgactgtgtc	tgccctgtccc
2761	caaacaggac	agcactggga	acctagctac	actgagcagg	gagaccatgc	ctcccagagc
2821	ttgttgtctc	cacttgtata	tatggatcag	aggagtaa	aattggaaaa	gtaatcagca
2881	tatgtgtaaa	gatttataca	gttggaaaact	tgtaatcttc	cccaggagga	gaagaagggt
2941	tctggagcag	tggactgcca	caagccacca	tgtaaccctt	ctcacctgcc	gtgcgttctg
3001	gctgtggacc	agtaggactc	aagggtggacg	tgcgttctgc	cttccttggt	aattttgtaa
3061	taattggaga	agatttatgt	cagcacacac	ttacagagca	caaatgcagt	atatagggtgc
3121	tggatgtatg	taaatatatt	caaattatgt	ataaatatat	attatatatt	tacaaggagt
3181	tattttttgt	attgatttta	aatggatgtc	ccaatgcacc	tagaaaattg	gtctctcttt
3241	ttttaatagc	tatttgctaa	atgctgttct	tacacataat	ttcttaattt	tcaccgagca
3301	gaggtggaaa	aatacttttg	ctttcaggga	aaatgggtata	acgttaattt	attaataaat
3361	tggtaatata	caaaacaatt	aatcatttat	agtttttttt	gtaatttaag	tggcatttct
3421	atgcaggcag	cacagcagac	tagttaatct	attgcttgga	cttaactagt	tatcagatcc
3481	tttggaaaaga	gaatatattac	aatatatgac	taatttgggg	aaaatgaagt	tttgatttat
3541	ttgtggttaa	atgctgctgt	cagacgattg	ttcttagacc	tcctaaatgc	cccatattaa
3601	aagaactcat	tcataggaag	gtgttttcatt	ttggtgtgca	accctgtcat	tacgtcaacg
3661	caacgtctaa	ctggacttcc	caagataaat	ggtaccagcg	tcctcttaaa	agatgcctta
3721	atccattcct	tgaggacaga	ccttagttga	aatgatagca	gaatgtgctt	ctctctggca
3781	gctggccttc	tgcttctgag	ttgcacatta	atcagattag	cctgattctc	ttcagtgaat
3841	tttgataatg	gcttccagac	tctttgcgtt	ggagacgcct	gttaggatct	tcaagtccca
3901	tcatagaaaa	ttgaaacaca	gagttgttct	gctgatagtt	ttggggatac	gtccatcttt
3961	ttaagggatt	gctttcatct	aattctggca	ggacctcacc	aaaagatcca	gcctcatacc
4021	tacatcagac	aaaatatcgc	cgttgttcct	tctgtactaa	agtattgtgt	tttgctttgg
4081	aaacaccac	tcactttgca	atagccgtgc	aagatgaatg	cagattacac	tgatcttatg
4141	tgttacaaaa	ttggagaaa	tatttaataa	aacctgttaa	tttttatact	gacaataaaa
4201	atgtttctac	agatattaat	gttaacaaga	caaaataaat	gtcacgcaac	ttaaaaaaaa
4261	aaaaaaaa					